Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.

Abstract

BACKGROUND:

Phosphodiesterase 4 (PDE4), which catalyses the conversion of cyclic adenosine 3',5'-monophosphate (cAMP) to 5'-AMP, plays a critical role in the pathogenesis of inflammatory disorders. Pruritus is the main symptom of dermatitides, such as atopic dermatitis, and is very difficult to control. Recent studies have shown that the activation of proteinase-activated receptor 2 (PAR2) is involved in pruritus in dermatoses in humans and rodents.

OBJECTIVE:

To investigate the inhibitory effect of E6005, a topically effective PDE4 inhibitor, on PAR2-associated itching in mice.

METHODS:

Mice were given an intradermal injection of SLIGRL-NH2 (100 nmol/site), a PAR2 agonist peptide, into the rostral part of the back. E6005 and 8-bromo-cAMP were applied topically and injected intradermally, respectively, to the same site. Scratching bouts were observed as an itch-related behavior, and firing activity of the cutaneous nerve was electrophysiologically recorded. Keratinocytes were isolated from the skin of neonatal mice and cultured for in vitro experiments. The concentrations of cAMP and leukotriene B4 (LTB4) were measured by enzyme immunoassay. The distribution of PDE4 subtypes in the skin was investigated by immunostaining.

RESULTS:

Topical E6005 and intradermal 8-bromo-cAMP significantly inhibited SLIGRL-NH2-induced scratching and cutaneous nerve firing. Topical E6005 increased cutaneous cAMP content. Topical E6005 and intradermal 8-bromo-cAMP inhibited cutaneous LTB4 production induced by SLIGRL-NH2, which has been shown to elicit LTB4-mediated scratching. E6005 and 8-bromo-cAMP inhibited SLIGRL-NH2-induced LTB4 production in the cultured murine keratinocytes also. PDE4 subtypes were mainly expressed in keratinocytes and mast cells in the skin.

CONCLUSIONS:

The results suggest that topical E6005 treatment inhibits PAR2-associated itching. Inhibition of LTB4 production mediated by an increase in cAMP may be partly involved in the antipruritic action of E6005.

• Authors: Tsugunobu Andoh, Yasushi Kuraishi
• Journal: Journal of dermatological science (J Dermatol Sci) Vol. 76 Issue 3 Pg. 206-13 (Dec 2014) ISSN: 1873-569X [Electronic] Netherlands
• PMID: 25458869 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antipruritics
• Oligopeptides
• Phosphodiesterase 4 Inhibitors
• Phthalic Acids
• Quinazolines
• Receptor, PAR-2
• methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate
• seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide
• Leukotriene B4
• 8-Bromo Cyclic Adenosine Monophosphate
• Cyclic AMP
• Cyclic Nucleotide Phosphodiesterases, Type 4
• Tpsab1 protein, mouse
• Tryptases

Topics

• 8-Bromo Cyclic Adenosine Monophosphate (administration & dosage)
• Administration, Topical
• Animals
• Antipruritics (administration & dosage, pharmacology)
• Cells, Cultured
• Cyclic AMP (metabolism)
• Cyclic Nucleotide Phosphodiesterases, Type 4 (classification, metabolism)
• Injections, Intradermal
• Keratinocytes (drug effects, metabolism)
• Leukotriene B4 (biosynthesis)
• Male
• Mice
• Mice, Inbred ICR
• Oligopeptides (administration & dosage)
• Phosphodiesterase 4 Inhibitors (administration & dosage, pharmacology)
• Phthalic Acids (administration & dosage, pharmacology)
• Pruritus (drug therapy, etiology, metabolism)
• Quinazolines (administration & dosage, pharmacology)
• Receptor, PAR-2 (agonists, antagonists & inhibitors)
• Skin (drug effects, innervation, metabolism)
• Tryptases (metabolism)